1	Lício	_	_	NNP	_	_	_	_	_
2	Velloso	_	_	NNP	_	_	_	_	_


1	Licio	_	_	NNP	_	_	_	_	_


1	Augusto	_	_	NNP	_	_	_	_	_


1	Velloso	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	Brazilian	_	_	JJ	_	_	_	_	_
5	full	_	_	JJ	_	_	_	_	_
6	professor	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	medicine	_	_	NN	_	_	_	_	_
9	at	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	University	_	_	NNP	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	Campinas	_	_	NNP	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Education	_	_	NN	_	_	_	_	_


1	Lício	_	_	NNP	_	_	_	_	_
2	Velloso	_	_	NNP	_	_	_	_	_
3	obtained	_	_	VBD	_	_	_	_	_
4	his	_	_	PRP$	_	_	_	_	_
5	MD	_	_	NNP	_	_	_	_	_
6	degree	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	1986	_	_	CD	_	_	_	_	_
9	from	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	University	_	_	NNP	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	Campinas	_	_	NNP	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	He	_	_	PRP	_	_	_	_	_
2	then	_	_	RB	_	_	_	_	_
3	attended	_	_	VBD	_	_	_	_	_
4	Uppsala	_	_	NNP	_	_	_	_	_
5	University	_	_	NNP	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	Sweden	_	_	NNP	_	_	_	_	_
8	from	_	_	IN	_	_	_	_	_
9	which	_	_	WDT	_	_	_	_	_
10	he	_	_	PRP	_	_	_	_	_
11	graduated	_	_	VBD	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	1993	_	_	CD	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	then	_	_	RB	_	_	_	_	_
16	served	_	_	VBD	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	postdoc	_	_	NN	_	_	_	_	_
20	at	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	Mario	_	_	NNP	_	_	_	_	_
23	Saad	_	_	NNP	_	_	_	_	_
24	Lab	_	_	NNP	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	University	_	_	NNP	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	Campinas	_	_	NNP	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	at	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	Ron	_	_	NNP	_	_	_	_	_
33	Kahn	_	_	NNP	_	_	_	_	_
34	Lab	_	_	NNP	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	Harvard	_	_	NNP	_	_	_	_	_
37	University	_	_	NNP	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	1994	_	_	CD	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	1995	_	_	CD	_	_	_	_	_
42	respectively	_	_	RB	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_
44	[	_	_	-LRB-	_	_	_	_	_
45	1	_	_	CD	_	_	_	_	_
46	]	_	_	-RRB-	_	_	_	_	_


1	He	_	_	PRP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	postdoctoral	_	_	JJ	_	_	_	_	_
5	fellow	_	_	NN	_	_	_	_	_
6	at	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	Joslin	_	_	NNP	_	_	_	_	_
9	Diabetes	_	_	NNP	_	_	_	_	_
10	Center	_	_	NNP	_	_	_	_	_
11	[	_	_	-LRB-	_	_	_	_	_
12	2	_	_	CD	_	_	_	_	_
13	]	_	_	-RRB-	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	coordinator	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	Obesity	_	_	NNP	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	Comorbidities	_	_	NNP	_	_	_	_	_
22	Research	_	_	NNP	_	_	_	_	_
23	Center	_	_	NNP	_	_	_	_	_
24	at	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	University	_	_	NNP	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	Campinas	_	_	NNP	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_
30	[	_	_	-LRB-	_	_	_	_	_
31	3	_	_	CD	_	_	_	_	_
32	]	_	_	-RRB-	_	_	_	_	_


1	Research	_	_	NN	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	2001	_	_	CD	_	_	_	_	_
3	he	_	_	PRP	_	_	_	_	_
4	studied	_	_	VBD	_	_	_	_	_
5	type	_	_	NN	_	_	_	_	_
6	2	_	_	CD	_	_	_	_	_
7	diabetes	_	_	NNS	_	_	_	_	_
8	along	_	_	IN	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	Claudio	_	_	NNP	_	_	_	_	_
11	Teodoro	_	_	NNP	_	_	_	_	_
12	de	_	_	NNP	_	_	_	_	_
13	Souza	_	_	NNP	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	back-then	_	_	JJ	_	_	_	_	_
17	Ph.D.	_	_	NN	_	_	_	_	_
18	student	_	_	NN	_	_	_	_	_
19	at	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	Cell	_	_	NNP	_	_	_	_	_
22	Signaling	_	_	NNP	_	_	_	_	_
23	Laboratory	_	_	NNP	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Their	_	_	PRP$	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	revealed	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	disease	_	_	NN	_	_	_	_	_
7	reoccurs	_	_	VBZ	_	_	_	_	_
8	when	_	_	WRB	_	_	_	_	_
9	pancreas	_	_	NN	_	_	_	_	_
10	fail	_	_	VBP	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	supply	_	_	VB	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	peripheral	_	_	JJ	_	_	_	_	_
15	need	_	_	NN	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	insulin	_	_	NN	_	_	_	_	_
18	that	_	_	WDT	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	body	_	_	NN	_	_	_	_	_
21	needs	_	_	VBZ	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	According	_	_	VBG	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	Lício	_	_	NNP	_	_	_	_	_
4	Velloso	_	_	NNP	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	as	_	_	RB	_	_	_	_	_
7	long	_	_	RB	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	pancreas	_	_	NN	_	_	_	_	_
11	can	_	_	MD	_	_	_	_	_
12	produce	_	_	VB	_	_	_	_	_
13	insulin	_	_	NN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	maintain	_	_	VB	_	_	_	_	_
16	this	_	_	DT	_	_	_	_	_
17	need	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	blood	_	_	NN	_	_	_	_	_
21	glucose	_	_	NN	_	_	_	_	_
22	level	_	_	NN	_	_	_	_	_
23	remains	_	_	VBZ	_	_	_	_	_
24	stable	_	_	JJ	_	_	_	_	_
25	-	_	_	:	_	_	_	_	_
26	close	_	_	JJ	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	80	_	_	CD	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	90	_	_	CD	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	expected	_	_	VBN	_	_	_	_	_
33	for	_	_	IN	_	_	_	_	_
34	a	_	_	DT	_	_	_	_	_
35	healthy	_	_	JJ	_	_	_	_	_
36	person	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	But	_	_	CC	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	when	_	_	WRB	_	_	_	_	_
4	it	_	_	PRP	_	_	_	_	_
5	does	_	_	VBZ	_	_	_	_	_
6	fail	_	_	VB	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	glucose	_	_	NN	_	_	_	_	_
10	rises	_	_	VBZ	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	which	_	_	WDT	_	_	_	_	_
13	makes	_	_	VBZ	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	patient	_	_	NN	_	_	_	_	_
16	dependent	_	_	JJ	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	insulin	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	dependency	_	_	NN	_	_	_	_	_
3	can	_	_	MD	_	_	_	_	_
4	result	_	_	VB	_	_	_	_	_
5	into	_	_	IN	_	_	_	_	_
6	hyperinsulinemic	_	_	JJ	_	_	_	_	_
7	hypoglycemia	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	according	_	_	VBG	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	Velloso	_	_	NNP	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Under	_	_	IN	_	_	_	_	_
2	Velloso	_	_	NNP	_	_	_	_	_
3	's	_	_	POS	_	_	_	_	_
4	guidance	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	Souza	_	_	NNP	_	_	_	_	_
7	had	_	_	VBD	_	_	_	_	_
8	studied	_	_	VBN	_	_	_	_	_
9	alpha	_	_	NN	_	_	_	_	_
10	protein	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	injected	_	_	VBD	_	_	_	_	_
13	it	_	_	PRP	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	an	_	_	DT	_	_	_	_	_
16	insulin-producing	_	_	JJ	_	_	_	_	_
17	cell	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	While	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	result	_	_	NN	_	_	_	_	_
4	did	_	_	VBD	_	_	_	_	_
5	n't	_	_	RB	_	_	_	_	_
6	yield	_	_	VB	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	major	_	_	JJ	_	_	_	_	_
9	breakthrough	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	it	_	_	PRP	_	_	_	_	_
12	opened	_	_	VBD	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	possibility	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	developing	_	_	VBG	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	drug	_	_	NN	_	_	_	_	_
19	that	_	_	WDT	_	_	_	_	_
20	would	_	_	MD	_	_	_	_	_
21	reduce	_	_	VB	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	action	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	PPARGC1A	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	trials	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	which	_	_	WDT	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	duo	_	_	NN	_	_	_	_	_
8	conducted	_	_	VBD	_	_	_	_	_
9	revealed	_	_	VBN	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	it	_	_	PRP	_	_	_	_	_
12	does	_	_	VBZ	_	_	_	_	_
13	indeed	_	_	RB	_	_	_	_	_
14	reduces	_	_	VBZ	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	production	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	alpha	_	_	NN	_	_	_	_	_
19	protein	_	_	NN	_	_	_	_	_
20	while	_	_	IN	_	_	_	_	_
21	increases	_	_	VBZ	_	_	_	_	_
22	insulin	_	_	NN	_	_	_	_	_
23	production	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Not	_	_	RB	_	_	_	_	_
2	only	_	_	RB	_	_	_	_	_
3	did	_	_	VBD	_	_	_	_	_
4	it	_	_	PRP	_	_	_	_	_
5	increase	_	_	VB	_	_	_	_	_
6	insulin	_	_	NN	_	_	_	_	_
7	production	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	but	_	_	CC	_	_	_	_	_
10	it	_	_	PRP	_	_	_	_	_
11	also	_	_	RB	_	_	_	_	_
12	decrease	_	_	VBP	_	_	_	_	_
13	diabetes	_	_	NN	_	_	_	_	_
14	occurrence	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_
16	[	_	_	-LRB-	_	_	_	_	_
17	4	_	_	CD	_	_	_	_	_
18	]	_	_	-RRB-	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	two	_	_	CD	_	_	_	_	_
3	years	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	he	_	_	PRP	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	Marciane	_	_	NNP	_	_	_	_	_
8	Milanski	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	nutritionist	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	had	_	_	VBD	_	_	_	_	_
14	studied	_	_	VBN	_	_	_	_	_
15	obesity	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	rats	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	it	_	_	PRP	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	suggested	_	_	VBN	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	it	_	_	PRP	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	possible	_	_	JJ	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	make	_	_	VB	_	_	_	_	_
14	brain	_	_	NN	_	_	_	_	_
15	control	_	_	NN	_	_	_	_	_
16	liver	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	order	_	_	NN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	maintain	_	_	VB	_	_	_	_	_
21	glycemic	_	_	JJ	_	_	_	_	_
22	balance	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	When	_	_	WRB	_	_	_	_	_
2	it	_	_	PRP	_	_	_	_	_
3	does	_	_	VBZ	_	_	_	_	_
4	happen	_	_	VB	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	hypothalamus	_	_	NN	_	_	_	_	_
8	becomes	_	_	VBZ	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	main	_	_	JJ	_	_	_	_	_
11	actor	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	this	_	_	DT	_	_	_	_	_
14	mechanism	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	research	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	along	_	_	RB	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	his	_	_	PRP$	_	_	_	_	_
7	comment	_	_	NN	_	_	_	_	_
8	:	_	_	:	_	_	_	_	_
9	"	_	_	``	_	_	_	_	_
10	The	_	_	DT	_	_	_	_	_
11	mechanism	_	_	NN	_	_	_	_	_
12	described	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	this	_	_	DT	_	_	_	_	_
15	research	_	_	NN	_	_	_	_	_
16	shows	_	_	VBZ	_	_	_	_	_
17	that	_	_	IN	_	_	_	_	_
18	control	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	high	_	_	JJ	_	_	_	_	_
21	glucose	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	fasting	_	_	NN	_	_	_	_	_
24	is	_	_	VBZ	_	_	_	_	_
25	done	_	_	VBN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	at	_	_	IN	_	_	_	_	_
28	least	_	_	JJS	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	part	_	_	NN	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	by	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	hypothalamus	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	reinforces	_	_	VBZ	_	_	_	_	_
3	our	_	_	PRP$	_	_	_	_	_
4	suspicion	_	_	NN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	development	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	drugs	_	_	NNS	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	action	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	central	_	_	JJ	_	_	_	_	_
15	nervous	_	_	JJ	_	_	_	_	_
16	system	_	_	NN	_	_	_	_	_
17	should	_	_	MD	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	interesting	_	_	JJ	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	treatment	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	diabetes	_	_	NNS	_	_	_	_	_
25	"	_	_	''	_	_	_	_	_
26	were	_	_	VBD	_	_	_	_	_
27	published	_	_	VBN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	American	_	_	NNP	_	_	_	_	_
31	Journal	_	_	NNP	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	Deabetes	_	_	NNP	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	2012	_	_	CD	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_
37	[	_	_	-LRB-	_	_	_	_	_
38	5	_	_	CD	_	_	_	_	_
39	]	_	_	-RRB-	_	_	_	_	_


1	From	_	_	IN	_	_	_	_	_
2	2005	_	_	CD	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	2007	_	_	CD	_	_	_	_	_
5	he	_	_	PRP	_	_	_	_	_
6	had	_	_	VBD	_	_	_	_	_
7	studied	_	_	VBN	_	_	_	_	_
8	human	_	_	JJ	_	_	_	_	_
9	diet	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	according	_	_	VBG	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	him	_	_	PRP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	studies	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	various	_	_	JJ	_	_	_	_	_
21	groups	_	_	NNS	_	_	_	_	_
22	have	_	_	VBP	_	_	_	_	_
23	shown	_	_	VBN	_	_	_	_	_
24	that	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	diet	_	_	NN	_	_	_	_	_
27	rich	_	_	JJ	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	simple	_	_	JJ	_	_	_	_	_
30	carbohydrates	_	_	NNS	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	can	_	_	MD	_	_	_	_	_
33	also	_	_	RB	_	_	_	_	_
34	increase	_	_	VB	_	_	_	_	_
35	lipid	_	_	NN	_	_	_	_	_
36	levels	_	_	NNS	_	_	_	_	_
37	in	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	blood	_	_	NN	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	indirectly	_	_	RB	_	_	_	_	_
42	promote	_	_	VB	_	_	_	_	_
43	inflammation	_	_	NN	_	_	_	_	_
44	in	_	_	IN	_	_	_	_	_
45	the	_	_	DT	_	_	_	_	_
46	hypothalamus	_	_	NN	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_
48	[	_	_	-LRB-	_	_	_	_	_
49	3	_	_	CD	_	_	_	_	_
50	]	_	_	-RRB-	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	2018	_	_	CD	_	_	_	_	_
3	Lício	_	_	NNP	_	_	_	_	_
4	Velloso	_	_	NNP	_	_	_	_	_
5	studied	_	_	VBD	_	_	_	_	_
6	hunger	_	_	NN	_	_	_	_	_
7	strikes	_	_	NNS	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	divided	_	_	VBD	_	_	_	_	_
10	them	_	_	PRP	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	three	_	_	CD	_	_	_	_	_
13	categories	_	_	NNS	_	_	_	_	_
14	:	_	_	:	_	_	_	_	_
15	Absolute	_	_	JJ	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	total	_	_	JJ	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	partial	_	_	JJ	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	he	_	_	PRP	_	_	_	_	_
6	suggested	_	_	VBD	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	people	_	_	NNS	_	_	_	_	_
9	who	_	_	WP	_	_	_	_	_
10	do	_	_	VBP	_	_	_	_	_
11	partial	_	_	JJ	_	_	_	_	_
12	hunger	_	_	NN	_	_	_	_	_
13	strikes	_	_	NNS	_	_	_	_	_
14	could	_	_	MD	_	_	_	_	_
15	have	_	_	VB	_	_	_	_	_
16	more	_	_	RBR	_	_	_	_	_
17	severe	_	_	JJ	_	_	_	_	_
18	consequences	_	_	NNS	_	_	_	_	_
19	then	_	_	RB	_	_	_	_	_
20	those	_	_	DT	_	_	_	_	_
21	that	_	_	WDT	_	_	_	_	_
22	have	_	_	VBP	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	absolute	_	_	JJ	_	_	_	_	_
25	one	_	_	CD	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	absolute	_	_	JJ	_	_	_	_	_
7	strike	_	_	NN	_	_	_	_	_
8	only	_	_	RB	_	_	_	_	_
9	kidneys	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	heart	_	_	NN	_	_	_	_	_
12	fails	_	_	VBZ	_	_	_	_	_
13	after	_	_	IN	_	_	_	_	_
14	25	_	_	CD	_	_	_	_	_
15	days	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	being	_	_	VBG	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	strike	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	while	_	_	IN	_	_	_	_	_
23	strikers	_	_	NNS	_	_	_	_	_
24	who	_	_	WP	_	_	_	_	_
25	preferred	_	_	VBD	_	_	_	_	_
26	partial	_	_	JJ	_	_	_	_	_
27	ended	_	_	VBD	_	_	_	_	_
28	up	_	_	RP	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	liver	_	_	NN	_	_	_	_	_
31	complications	_	_	NNS	_	_	_	_	_
32	within	_	_	IN	_	_	_	_	_
33	40	_	_	CD	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	50	_	_	CD	_	_	_	_	_
36	days	_	_	NNS	_	_	_	_	_
37	after	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	strike	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	conclusion	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	what	_	_	WP	_	_	_	_	_
5	Dr.	_	_	NNP	_	_	_	_	_
6	Velloso	_	_	NNP	_	_	_	_	_
7	suggests	_	_	VBZ	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	people	_	_	NNS	_	_	_	_	_
11	who	_	_	WP	_	_	_	_	_
12	have	_	_	VBP	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	weak	_	_	JJ	_	_	_	_	_
15	heart	_	_	NN	_	_	_	_	_
16	should	_	_	MD	_	_	_	_	_
17	n't	_	_	RB	_	_	_	_	_
18	take	_	_	VB	_	_	_	_	_
19	too	_	_	RB	_	_	_	_	_
20	much	_	_	JJ	_	_	_	_	_
21	liquid	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	otherwise	_	_	RB	_	_	_	_	_
24	it	_	_	PRP	_	_	_	_	_
25	can	_	_	MD	_	_	_	_	_
26	lead	_	_	VB	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	heart	_	_	NN	_	_	_	_	_
29	failure	_	_	NN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	even	_	_	RB	_	_	_	_	_
32	death	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_
34	[	_	_	-LRB-	_	_	_	_	_
35	6	_	_	CD	_	_	_	_	_
36	]	_	_	-RRB-	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	October	_	_	NNP	_	_	_	_	_
3	30	_	_	CD	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	2018	_	_	CD	_	_	_	_	_
6	he	_	_	PRP	_	_	_	_	_
7	appeared	_	_	VBD	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	interview	_	_	NN	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	Paulo	_	_	NNP	_	_	_	_	_
13	Saldiva	_	_	NNP	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	Science	_	_	NNP	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	Health	_	_	NNP	_	_	_	_	_
18	program	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	Futura	_	_	NNP	_	_	_	_	_
22	Chanel	_	_	NNP	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_
24	[	_	_	-LRB-	_	_	_	_	_
25	7	_	_	CD	_	_	_	_	_
26	]	_	_	-RRB-	_	_	_	_	_


1	Editorial	_	_	JJ	_	_	_	_	_
2	work	_	_	NN	_	_	_	_	_


1	He	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	former	_	_	JJ	_	_	_	_	_
5	member	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	editorial	_	_	JJ	_	_	_	_	_
9	board	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	Clinical	_	_	NNP	_	_	_	_	_
12	Endocrinology	_	_	NNP	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	current	_	_	JJ	_	_	_	_	_
15	member	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	editorial	_	_	JJ	_	_	_	_	_
19	board	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	International	_	_	NNP	_	_	_	_	_
22	Journal	_	_	NNP	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	Obesity	_	_	NNP	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_
26	[	_	_	-LRB-	_	_	_	_	_
27	8	_	_	CD	_	_	_	_	_
28	]	_	_	-RRB-	_	_	_	_	_

